.2020 .. Kidney: Globocan 2020 - The Global Cancer Observatory. Globocan, 419 : 1-2.
Hu B,Wang J,Jin X. .2017 .MicroRNA-138 suppresses cell proliferation and invasion of renal cell carcinoma by directly targeting SOX9. Oncol Lett, 7160(6) : 7583-8.
Harb OA,Elfeky MA,El Shafaay BS,Taha HF,Osman G,Harera IS .2018 .SPOP, ZEB-1 and E-cadherin expression in clear cell renal cell carcinoma (cc-RCC): Clinicopathological and prognostic signi cance. Pathophysiology, 05(4) : 335-45.
Aguilar-Medina M,Avendano-Felix M,Lizarraga-Verdugo E,Bermudez M,Romero-Quintana JG,Ramos-Payan R .2019 .SOX9 Stem-cell factor: Clinical and functional relevance in cancer. J Oncol, 10 : .
Siljee S,Milne B,Brasch HD,Bockett N,Patel J,Davis PF .2021 .Expression of components of the renin-angiotensin system by cancer stem cells in renal clear cell carcinoma. Biomolecules, 10(4) : 537.
Liu Y,Zhang C,Fan J,Xiao L,Yin B,Zhou Le .2011 .Comprehensive analysis of clinical signi cance of stem-cell related factors in renal cell cancer. World J Surg Oncol, 10(1) : 1477.
Chen W,Zhao W,Chen S,Zhang L,Guo Z,Wang L .2018 .Expression and correlation of MALAT1 andSOX9 in nonsmall cell lung cancer. Clin Respir J, 10(7) : 2284-91.
Wan YP,Xi M,He HC,Wan S,Hua W,Zen ZC .2017 .Expression and clinical signi cance oSfOX9 in renal cell carcinoma, bladder cancer and penile cancer. Oncol Res Treat, 10(1-2) : 15-20.
Jang N-R,Choi JH,Gu MJ JH .2021 .Aberrant Expression of E-cadherin, N-cadherin, and P-cadherin in clear cell renal cell carcinoma: Association with adverse clinicopathologic factors and poor prognosis. Appl Immunohistochem Mol Morphol, 10(3) : 223-30.
Mendonsa AM,Na TY,Gumbiner BM TY .2018 .E-cadherin in contact inhibition and cancer. Oncogene, 10(35) : 4769-80.
Gao Y,Yan Y,Guo J,Zhang Q,Bi D,Wang FEN .2019 .HNF 4 ± downregulation promotes tumour migration and invasion by regulating E cadherin in renal cell carcinoma. Oncol Rep, 7214(3) : 1066-74.
Wang D,Su L,Huang D,Zhang H,Shin DM,Chen ZG .2011 .Downregulation of E-cadherin enhances proliferation of head and neck cancer through transcriptional regulation of EGFR. Mol Cancer, 10 : 1476.
Evans PM,Liu C .2008 .Roles of Krupel-like factor 4 in normal homeostasis, cancer and stem cells. Acta Biochim Biophys Sin, 00439(7) : 7270-64.
Zhao W,Hisamuddin IM,Nandan MO,Babbin BA,Lamb NE,Yang VW .2004 .Identi cation of kruppel-like factor 4 as a potential tumour suppressor gene in colorectal cancer. Oncogene, 1207067(2) : 395-402.
Zhang N,Su P,Li X,Xi J,Li XU,Xu LUO .2019 .Downregulated kruppel-like factor 4 expression is associated with the aggressiveness of prostate cancer. Oncol Rep, 6975(3) : 1789-96.
Song E,Ma X,Li H,Zhang P,Ni D,Chen W .2013 .Attenuation of kruppel-like factor 4 facilitates carcinogenesis by inducing g1/s phase arrest in clear cell renal cell carcinoma. PLoS One, 0067758(7) : .
Moch H,Amin MB,Argani P,Cheville JDB,Martignoni G,Medeiros LJ,Holger M,Peter HA,Thomas UM,Reuter VE .2016 .of Tumours of the Urinary System and Male Genital Organs. , : 12-21.
Li XL,Chen XQ,Zhang MN,Chen N,Nie L,Xu M .2015 .SOX9 was involved in TKIs resistance in renal cell carcinomavia Raf/MEK/ERK signaling pathway. Int J Clin Exp Pathol, 8(4) : 3871-81.
Andreiana BC,Stepan AE,Margaritescu C,Taisescu O,Osman A,Simionescu C .2019 .Snail andE-cadherin immunoexpression in clear cell renal cell carcinoma. Curr Heal Sci J, 10(2) : 185-9.
Cai J .2013 .Roles of transcriptional factor snail and adhesion factor E-cadherin in clear cell renal cell carcinoma. Exp Ther Med, 10(6) : 1489-93.
Langner C,Ratschek M,Rehak P,Schips L,Zigeuner R .2004 .Expression of MUC1 (EMA) andE-cadherin in renal cell carcinoma/: A systematic immunohistochemical analysis of 188 cases. Mod Pathol, 10(20) : 180-8.
Li H,Wang J,Xiao W,Xia D,Lang B,Yu G .2013 .Epigenetic alterations of kruppel-like factor 4 and its tumour suppressor function in renal cell carcinoma. Carcinogenesis, 10(10) : 2262-70.
Chen W,Wang H,Lu Y,Huang Y,Xuan Y,Li X .2022 .GTSE1 promotes tumour growth and metastasis by attenuating of KLF4 expression in clear cell renal cell carcinoma. Lab Invest, 10(9) : 1011-22.